Angiotensin II 血管紧张素 II 品牌:FUJIFILM Wako


Angiotensin II

血管紧张素 II

品牌:FUJIFILM Wako
CAS No.:4474-91-3
储存条件:-20℃
纯度:97.0+% (HPLC)
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

014-18211

for Biochemistry 10 mg

Angiotensin II                                                      血管紧张素 II            品牌:FUJIFILM Wako

替代品:015-27911


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。

Angiotensin I/II (1-5)

Angiotensin I/II (1-5);

Angiotensin I/II 1-5 是由 1-5 个氨基酸组成的多肽,由血管紧张素 I/II 肽转化而来。血管紧张素 I 是由肾素对血管紧张素原的作用形成的。血管紧张素 II 是由血管紧张素 I 产生的。血管紧张素 II 用于高血压、肾素-血管紧张素系统和特发性膜性肾病的研究、基础科学和诊断中。

Angiotensin I/II (1-5)amp;;

Angiotensin I/II (1-5) Chemical Structure

CAS No. : 58442-64-1

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].

分子量

664.75

Formula

C30H48N8O9

CAS 号

58442-64-1

Sequence Shortening

DRVYI

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Erdös EG, et al. Conversion of angiotensin I to angiotensin II. Am J Med. 1976 May 31;60(6):749-59.

    [2]. Angiotensin I

    [3]. Angiotensin II

Angiotensin (1-7)(Synonyms: Ang-(1-7))

Angiotensin (1-7);(Synonyms: Ang-(1-7))

Angiotensin 1-7 (Ang-(1-7)) 是肾素-血管紧张素系统 (RAS) 中的一种内源性七肽,由于其在心肌细胞中的抗炎和抗纤维化活性而具有心脏保护作用。Angiotensin 1-7 抑制纯化的犬血管紧张素转换酶 (ACE) 活性,IC50 值为 0.65 μM。Angiotensin 1-7 通过抑制血管紧张素转换酶和释放一氧化氮,可作为激肽诱导的血管舒张的局部协同调节剂。Angiotensin 1-7 阻断 Ang II 诱导的平滑肌细胞增殖和肥大,并显示对内皮的抗血管生成和生长抑制作用。Angiotensin 1-7 显示出抗炎活性。

Angiotensin (1-7)amp;;(Synonyms: Ang-(1-7))

Angiotensin (1-7) Chemical Structure

CAS No. : 51833-78-4

规格 价格 是否有货 数量
10;mM;*;1 mL in Water ¥801 询价
5 mg ¥520 In-stock
10 mg ¥810 询价
25 mg ¥1800 询价
50 mg ¥2850 询价
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Angiotensin (1-7) 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • Peptidomimetic Library
  • Anti-Cardiovascular Disease Compound Library
  • Endocrinology Compound Library
  • Orally Active Compound Library
  • Neurotransmitter Receptor Compound Library
  • Neuroprotective Compound Library
  • Angiogenesis Related Compound Library
  • Rare Diseases Drug Library

生物活性

Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity [1][2][3].

IC50 Target

IC50: 0.65 μM (ACE)[2]

体外研究
(In Vitro)

Angiotensin 1-7 (Ang-(1-7)) inhibits cultured vascular smooth muscle cell growth, whereas equal molar concentration of Ang II stimulates cell growth[2].
Angiotensin 1-7 (Ang 1-7) abrogates the methylglyoxal-modified albumin (MGA)-stimulated myofibroblast phenotype by inhibiting the chronic stimulation of the TGF-β-ERK pathway in NRK-52E cells[4].
Angiotensin 1-7 signals through the Mas receptor ( MasR) in opposition to Ang II/angiotensin II type 1 receptor (AT1R), promoting anti-inflammatory,vasodilatory, and neuroprotective effects[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Daily Angiotensin 1-7 (Ang-(1-7)) treatment (0.01-0.06 mg/kg) results in significant amelioration of DSS-induced colitis. Colitis-associated phosphorylation of p38, ERK1/2 and Akt is reduced by Ang 1-7 treatment[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

899.00

Formula

C41H62N12O11

CAS 号

51833-78-4

Sequence

Asp-Arg-Val-Tyr-Ile-His-Pro

Sequence Shortening

DRVYIHP

中文名称

血管紧张素 (1-7)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

H2O : ≥ 30.2 mg/mL (33.59 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1123 mL 5.5617 mL 11.1235 mL
5 mM 0.2225 mL 1.1123 mL 2.2247 mL
10 mM 0.1112 mL 0.5562 mL 1.1123 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Gómez-Mendoza DP, et al. Angiotensin-(1-7) oral treatment after experimental myocardial infarction leads to downregulation of CXCR4. J Proteomics. 2019;208:103486.

    [2]. Li P, et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997 Jan;29(1 Pt 2):394-400.

    [3]. Khajah MA, et al. Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis. PLoS One. 2016 Mar 10;11(3):e0150861.

    [4]. Alzayadneh EM, et al. Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2. Cell Signal. 2014 Sep 19. pii: S0898-6568(14)00314-3.

    [5]. Janatpour ZC, et al. Subcutaneous Administration of Angiotensin-(1-7) Improves Recovery after Traumatic Brain Injury in Mice. J Neurotrauma. 2019;36(22):3115-3131.

Kinase Assay
[1]

Competition assays using purified canine ACE are determined using a fixed concentration of the substrate Hip-His-Leu (1 mM) and varying the concentrations of the competing agents [Lisinopril (0.1 to 100 nM), Angiotensin (1-7) (10 nM to 10 μM), or Sar1, Thr8-Ang II (10 nM to 10 μM)]. Inhibitory constants (IC50) are determined from the respective competition curves. To study the effect of Angiotensin (1-7) on BK metabolism in intact coronary rings, 125I-[Tyr0]-BK (final concentration of 1 nM) is added to the tubes containing three rings preincubated with 1 mL Krebs’ buffer and aerated with 95% O2 and 5% CO2 at 37°C. Lisinopril (2 μM), Angiotensin (1-7) (2 μM), or Krebs’ buffer as control are added to the rings 10 minutes before addition of the radiolabeled BK. Aliquots of the incubation medium are removed at 5, 10, and 20 minutes and diluted with 1% HFBA to inhibit peptidase activity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

500 μM Methylglyoxal is incubated with 100 μM BSA dissolved in phosphate buffered saline (PBS) for 24 hours, then washed on 10 kDa filters to remove excess methyl glyoxal, reconstituted with DMEM/F12 serum free media and passed through a 0.2 μmicron filter. TGF-β (5 ng/mL) is prepared to treat cells in a subset of experiments. Cells are co-treated with one or combinations of the following: Angiotensin (1-7) (100 nM), D-Ala7-Ang-(1-7) (10 μM), ERK1/2 kinase inhibitor, PD 98059 (1 μM), TGF-β receptor kinase inhibitor; SB525334 (1 μM), the AT1 receptor antagonist Losartan (1 μM), the renin inhibitor Aliskerin (1 μM) and the ACE inhibitor Lisinopril (1 μM)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3][4]

Mice[3]
Male and female BALB/c mice (1:1 ratio, 6-10 weeks old, mean weight 20 g.) are used. Angiotensin fragment 1-7 acetate salt hydrate (Ang 1-7) is dissolved in 0.9% saline (vehicle) at 1 mg/mL and stored at -80°C. Various doses (0.01, 0.06, 0.1, 0.3 and 1 mg/kg) are freshly prepared from the stock each day of the experiment, and administered to mice by daily intra-peritoneal (i.p) injections in a volume of 500 μL per injection, either before (prophylactic approach) or after (treatment approach) DSS treatment. A779 (MAS-1 R antagonist) is similarly dissolved in distilled water at 1 mg/mL and stored at -80°C. A freshly prepared dose of 1 mg/kg is administered to a second group of mice by daily i.p injections in a volume of 500 μL daily (for 4 days) along with colitis induction (prophylactic approach). A third group of mice receive DSS containing water and daily i.p injections of 0.9% saline (vehicle). The fourth group receive DSS containing water along with daily i.p injections with Dexamethasone (DEX) at doses of 0.01-1.0 mg/kg or its vehicle (0.9% saline) (prophylactic approach).
Rats[4]
Twenty six ovariectomized female Wistar rats weighing 200±20 g are used. Angiotensin (1-7) is administered intravenously by a microsyringe pump at two different continuous doses of 100 and 300 ng/kg/min after antagonist/saline infusion. Each dose is infused for 15 min; and MAP, RPP, and RBF are recorded during Angiotensin (1-7) infusion and the last 3-5 min of each dose measured as “response to Angiotensin (1-7) infusion”. During Angiotensin (1-7) infusion, RPP is sustained at pre-Ang1-7 infusion levels via an adjustable aortic clamp.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Gómez-Mendoza DP, et al. Angiotensin-(1-7) oral treatment after experimental myocardial infarction leads to downregulation of CXCR4. J Proteomics. 2019;208:103486.

    [2]. Li P, et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997 Jan;29(1 Pt 2):394-400.

    [3]. Khajah MA, et al. Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis. PLoS One. 2016 Mar 10;11(3):e0150861.

    [4]. Alzayadneh EM, et al. Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2. Cell Signal. 2014 Sep 19. pii: S0898-6568(14)00314-3.

    [5]. Janatpour ZC, et al. Subcutaneous Administration of Angiotensin-(1-7) Improves Recovery after Traumatic Brain Injury in Mice. J Neurotrauma. 2019;36(22):3115-3131.

4-Hydroxychalcone

天然产物 黄酮类 Flavonoids

4-Hydroxychalcone  纯度: 99.65%

4-Hydroxychalcone 是查尔酮代谢物,具有抗血管生成和消炎作用。 4-Hydroxychalcone 通过抑制生长因子途径抑制血管生成,无细胞毒性迹象。4-Hydroxychalcone 抑制 TNF-α 诱导的 NF-κB 途径活化并激活 BMP 信号传导,通过减轻小鼠的醛固酮过多症和肾脏损伤来降低抵抗性高血压 (RH)。

4-Hydroxychalcone

4-Hydroxychalcone Chemical Structure

CAS No. : 20426-12-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥550 In-stock
100 mg ¥500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

4-Hydroxychalcone 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Phenols Library
  • Pyroptosis Compound Library
  • Flavonoids Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library

生物活性

4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity[1]. 4-Hydroxychalcone inhibits TNF-α induced NF-κB pathway activation and activates BMP signaling, reduces resistant hypertension (RH) by attenuating hyperaldosteronism and renal injury in mice[2].

IC50 & Target

NF-κB[2]

分子量

224.25

Formula

C15H12O2

CAS 号

20426-12-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : ≥ 250 mg/mL (1114.83 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.4593 mL 22.2965 mL 44.5931 mL
5 mM 0.8919 mL 4.4593 mL 8.9186 mL
10 mM 0.4459 mL 2.2297 mL 4.4593 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (9.28 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (9.28 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (9.28 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (9.28 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Varinska L, et al. Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. Eur J Pharmacol. 2012 Sep 15;691(1-3):125-33.

    [2]. Qu Q, et al. 4-Hydroxychalcone attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice. Biomed Res Int. 2014;2014:603415.

Angiotensin (1-7) (acetate)(Synonyms: Ang-(1-7) (acetate))

Angiotensin (1-7) (acetate);(Synonyms: Ang-(1-7) (acetate)) 纯度: 98.91%

Angiotensin 1-7 (Ang-(1-7)) acetate 是肾素-血管紧张素系统 (RAS) 中的一种内源性七肽,由于其在心肌细胞中的抗炎和抗纤维化活性而具有心脏保护作用。Angiotensin 1-7 acetate 抑制纯化的犬血管紧张素转换酶 (ACE) 活性(IC50=0.65 μM)。Angiotensin 1-7 acetate 通过抑制血管紧张素转换酶和释放一氧化氮作为激肽诱导的血管舒张的局部协同调节剂。Angiotensin 1-7 acetate 阻断血管紧张素 Ⅱ 诱导的平滑肌细胞增殖和肥大,对内皮细胞具有抗血管生成和生长抑制作用。

Angiotensin (1-7) (acetate)amp;;(Synonyms: Ang-(1-7) (acetate))

Angiotensin (1-7) (acetate) Chemical Structure

规格 价格 是否有货 数量
10;mM;*;1 mL in Water ¥855 In-stock
5 mg ¥520 In-stock
10 mg ¥810 In-stock
25 mg ¥1800 In-stock
50 mg ¥2850 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Angiotensin (1-7) (acetate) 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Endocrinology Compound Library
  • Orally Active Compound Library
  • Neurotransmitter Receptor Compound Library
  • Neuroprotective Compound Library
  • Angiogenesis Related Compound Library
  • Rare Diseases Drug Library
  • Peptide Library

生物活性

Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium[1][2][3].

IC50 Target

IC50: 0.65 μM (ACE)[2]

体外研究
(In Vitro)

Angiotensin 1-7 (Ang-(1-7)) inhibits cultured vascular smooth muscle cell growth, whereas equal molar concentration of Ang II stimulates cell growth[2].
Angiotensin 1-7 (Ang 1-7) abrogates the methylglyoxal-modified albumin (MGA)-stimulated myofibroblast phenotype by inhibiting the chronic stimulation of the TGF-β-ERK pathway in NRK-52E cells[4].
Angiotensin 1-7 signals through the Mas receptor ( MasR) in opposition to Ang II/angiotensin II type 1 receptor (AT1R), promoting anti-inflammatory,vasodilatory, and neuroprotective effects[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Daily Angiotensin 1-7 (Ang-(1-7)) treatment (0.01-0.06 mg/kg) results in significant amelioration of DSS-induced colitis. Colitis-associated phosphorylation of p38, ERK1/2 and Akt is reduced by Ang 1-7 treatment[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

959.06

Formula

C43H66N12O13

Sequence

Asp-Arg-Val-Tyr-Ile-His-Pro

Sequence Shortening

DRVYIHP

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

H2O : 62.5 mg/mL (65.17 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0427 mL 5.2134 mL 10.4269 mL
5 mM 0.2085 mL 1.0427 mL 2.0854 mL
10 mM 0.1043 mL 0.5213 mL 1.0427 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Gómez-Mendoza DP, et al. Angiotensin-(1-7) oral treatment after experimental myocardial infarction leads to downregulation of CXCR4. J Proteomics. 2019;208:103486.

    [2]. Li P, et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997 Jan;29(1 Pt 2):394-400.

    [3]. Khajah MA, et al. Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis. PLoS One. 2016 Mar 10;11(3):e0150861.

    [4]. Alzayadneh EM, et al. Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2. Cell Signal. 2014 Sep 19. pii: S0898-6568(14)00314-3.

    [5]. Janatpour ZC, et al. Subcutaneous Administration of Angiotensin-(1-7) Improves Recovery after Traumatic Brain Injury in Mice. J Neurotrauma. 2019;36(22):3115-3131.

Aviptadil(Synonyms: 阿肽地尔 Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine))

Aviptadil;(Synonyms: 阿肽地尔; Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine))

Aviptadil 是一种血管活性肠多肽 (VIP) 类似物,具有强的血管舒张 (vasodilatory) 作用。Aviptadil 诱导肺血管扩张,抑制血管 SMCs 增殖、血小板聚集。Aviptadil 可用于肺纤维化、肺动脉高压 (PAH)、SARS-CoV-2 引起呼吸衰竭等的研究。

Aviptadil (Synonyms: 阿肽地尔; Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine))

Aviptadil Chemical Structure

CAS No. : 40077-57-4

规格 价格 是否有货 数量
1 mg ¥1200 In-stock
5 mg ¥2500 In-stock
10 mg ¥3500 In-stock
50 mg ¥6500 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al[1][2].

体外研究
(In Vitro)

Aviptadil inhibits the basal proliferation of pulmonary arterial smooth muscle cells (PASMC) and the mobilization of intracellular free calcium concentration in these cells in a dose-dependent manner[3].
Aviptadil (1 nM-10 μM) produces a concentration-dependent inhibition of CSE-induced cell death in L2 cells. At 10 μM, Aviptadil reduces CSE-stimulated MMP activity and caspase-3 activation in L2 cells[3].
Aviptadil (10 nM-100 μM) attenuates lipopolisaccharide (LPS)-induced MMP-9 activity and its expression by alveolar macrophages (AM) in rats[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Aviptadil (1, 3 and 10 mg/kg; intravenous bolus injection) is injected into a tail vein. No-effect dose level is 1 mg/kg. Dose level with first intolerance reactions 3 mg/kg, Lowest lethal dose level is >10 mg/kg. i.v. LD50 of Aviptadil is >10 mg/kg in males, females and male and female combined after 24 hours and 14 days[3].
Aviptadil (intravenous bolus injection) at 3 mg causes slightly reduced motility, slight ataxia and slight dyspnoea in all 5 male and 5 female animals 15 to 30 minutes after administration. At 10 mg, Aviptadil reveals slightly reduced motility, slight ataxia, and slight dyspnoea 15 to 60 minutes and slightly reduces muscle tone 15 to 30 minutes after administration, respectively, in all male and female animals[3].
Nose-only inhalation exposure of CD1 mice to aerosolized.
Aviptadil at a dose of 1546 µg/kg/day is well tolerated and produces no apparent changes in any of the parameters evaluated. No changes are observed after a single dose administration as high as 3920 µg/kg/day. The no-observable-adverse-effect level (NOAEL) is considered to be at least 3920 µg/kg/day fore an acute exposure and 1546 µg/kg/day for a 10 day repeated exposure[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

3325.80

Formula

C147H238N44O42S

CAS 号

40077-57-4

Sequence Shortening

HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2

中文名称

阿肽地尔

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro:;

H2O : 33.33 mg/mL (10.02 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.3007 mL 1.5034 mL 3.0068 mL
5 mM 0.0601 mL 0.3007 mL 0.6014 mL
10 mM 0.0301 mL 0.1503 mL 0.3007 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV)

    [2]. Jian Hu, et al. Novel Targets of Drug Treatment for Pulmonary Hypertension. Am J Cardiovasc Drugs

    [3]. INVESTIGATOR’S BROCHURE Sponsor: NeuroRx, Inc

Aviptadil acetate(Synonyms: 醋酸阿肽地尔 Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine))

Aviptadil acetate;(Synonyms: 醋酸阿肽地尔; Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)) 纯度: 99.09%

Aviptadil acetate 是一种模拟血管活性肠多肽 (VIP) 类似物,具有强的血管舒张 (vasodilatory) 效应。。Aviptadil acetate 诱导肺血管扩张,抑制血管 SMCs 增殖、血小板聚集。Aviptadil acetate 可用于肺纤维化、肺动脉高压 (PAH)、SARS-CoV-2 引起呼吸衰竭等的研究。

Aviptadil acetateamp;;(Synonyms: 醋酸阿肽地尔; Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine))

Aviptadil acetate Chemical Structure

CAS No. : 1444827-29-5

规格 价格 是否有货 数量
5 mg ¥2200 In-stock
10 mg ¥3500 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Aviptadil acetate 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Immunology/Inflammation Compound Library
  • FDA-Approved Drug Library
  • Antiviral Compound Library
  • Drug Repurposing Compound Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Rare Diseases Drug Library
  • Peptide Library

生物活性

Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al[1].

体外研究
(In Vitro)

Aviptadil acetate inhibits the basal proliferation of pulmonary arterial smooth muscle cells (PASMC) and the mobilization of intracellular free calcium concentration in these cells in a dose-dependent manner[3].
Aviptadil acetate (1 nM-10 μM) produces a concentration-dependent inhibition of CSE-induced cell death in L2 cells. At 10 μM, Aviptadil acetate reduces CSE-stimulated MMP activity and caspase-3 activation in L2 cells[1].
Aviptadil acetate (10 nM-100 μM) attenuates lipopolisaccharide (LPS)-induced MMP-9 activity and its expression by alveolar macrophages (AM) in rats[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Aviptadil acetate (1, 3 and 10 mg/kg; intravenous bolus injection) is injected into a tail vein. No-effect dose level is 1 mg/kg. Dose level with first intolerance reactions 3 mg/kg, Lowest lethal dose level is >10 mg/kg. i.v. LD50 of Aviptadil is >10 mg/kg in males, females and male and female combined after 24 hours and 14 days[3].
Aviptadil acetate (intravenous bolus injection) at 3 mg causes slightly reduced motility, slight ataxia and slight dyspnoea in all 5 male and 5 female animals 15 to 30 minutes after administration. At 10 mg, Aviptadil reveals slightly reduced motility, slight ataxia, and slight dyspnoea 15 to 60 minutes and slightly reduces muscle tone 15 to 30 minutes after administration, respectively, in all male and female animals[3].
Nose-only inhalation exposure of CD1 mice to aerosolized.
Aviptadil acetate at a dose of 1546 µg/kg/day is well tolerated and produces no apparent changes in any of the parameters evaluated. No changes are observed after a single dose administration as high as 3920 µg/kg/day. The no-observable-adverse-effect level (NOAEL) is considered to be at least 3920 µg/kg/day fore an acute exposure and 1546 µg/kg/day for a 10 day repeated exposure[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

3385.90

Formula

C147H238N44O42S.C2H4O2

CAS 号

1444827-29-5

Sequence Shortening

HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2

中文名称

醋酸阿肽地尔;醋酸阿维他定

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro:;

H2O : 100 mg/mL (29.53 mM; Need ultrasonic)

DMSO : 100 mg/mL (29.53 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.2953 mL 1.4767 mL 2.9534 mL
5 mM 0.0591 mL 0.2953 mL 0.5907 mL
10 mM 0.0295 mL 0.1477 mL 0.2953 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (0.74 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.74 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (0.74 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (0.74 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (0.74 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (0.74 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV)

    [2]. Jian Hu, et al. Novel Targets of Drug Treatment for Pulmonary Hypertension. Am J Cardiovasc Drugs

    [3]. INVESTIGATOR’S BROCHURE Sponsor: NeuroRx, Inc

内皮血管生成试剂盒—Endothelial Tube Formation Assay (Angiogenesis)

血管生成(Angiogenesis)是指源于已存在的毛细血管和毛细血管后微静脉的新的毛细血管性血管的生长。内皮血管生成是一个极其复杂的过程。通常新生血管是在原有的血管基础上延伸扩展而形成的,其过程类似于典型的伤口愈合和胚胎形成过程。在血管生成因子和趋化因子的作用下,血管内皮细胞分泌尿激酶型纤溶酶原激活物和抑制因子等蛋白酶,并穿过血管下基质膜向肿瘤组织迁移。一般包括包括血管内皮基质降解、内皮细胞移行、内皮细胞增殖、内皮细胞管道化分支形成血管环和形成新的基底膜等步骤。

对于血管生成的研究,已建立有多个体内(in vivi)模型。如鸡胚绒毛尿囊膜(CAM)模型,在体基质胶塞分析(Matrigel Plug Assay)、角膜血管再生分析(Corneal Angiogenesis Assay)等模型均能很好的评估血管生成应答和再生能力。然后这些体内模型都具有共同的缺陷:耗时耗力,并且需要成熟的技术和试验经验。

内皮血管生成试剂盒—Endothelial Tube Formation Assay (Angiogenesis)

针对上述问题,Cell Biolabs开发出的Endothelial Tube Formation Assay Kit内皮血管生成试剂盒以EHS肿瘤细胞分离的基质ECM组分胶作为三维培养基质,能让血管内皮细胞在18小时内形成血管。这种快速的检测血管再生能力的方案较真实的模拟了细胞生长和血管再生的环境,因此可用于血管再生能力的检测及血管生成抑制剂的快速筛选等。

产品名称 货号 产品说明(点击查看说明书)
Endothelial Tube Formation Assay (In Vitro Angiogenesis) CBA-200 光镜或荧光显微镜下50次分析

Cell Biolabs的内皮血管生成试剂盒提供了一个自动化的评估离体(in vitro)血管生成能力的方案。试剂盒内提供了ECM基质胶、荧光染料及缓冲液等。其操作步骤是将细胞铺设在基质ECM组分胶上,培养4-18小时后在光学显微镜下观察管道生成情况,包括管道的长度和节点数等。另外,试剂盒内还提供了荧光染料,可快速对细胞和新生管进行荧光显色观察和分析。该血管再生试剂盒能完成96孔板内的50次分析。

Cell BioLabs为您提供全套的细胞分析检测方案,针对于血管再生,提供了基于胶原蛋白的3D模型的快速检测方案。另外,Cell Biolabs还开发出其他多方位的基于细胞功能特征,特别是肿瘤细胞的特性的克隆形成、细胞的粘附分析、细胞伤口愈合实验、包括了细胞趋化及趋触以及游出的细胞迁移分析、细胞吞噬试验、细胞衰老及失巢凋亡,以及细胞收缩等多种分析试剂盒。如果您对上述细胞分析方案感兴趣,请致电021-50837765到上海金畔生物科技有限公司垂询细胞研究的相关实验解决方案,或索取最新的Cell BioLabs产品资料。

肿瘤细胞跨内皮迁移—CytoSelect™ Tumor Transendothelial Migration Assay

肿瘤细胞的浸润及血行转移是一个多步骤的,肿瘤细胞与宿主细胞相互作用的生物学过程,与肿瘤治疗的远期效果密切相关。大致步骤是原发灶肿瘤细胞的增殖;肿瘤细胞自原发灶游出,侵袭穿过细胞外基质和血管基底膜,游出至血管内;血液循环中的肿瘤细胞逃避免疫监视、与转移部位的血管内皮细胞相粘附,并穿过血管内皮细胞,游走至血管外;肿瘤细胞转移至目标脏器并增殖。肿瘤细胞跨内皮迁移—CytoSelect™ Tumor Transendothelial Migration Assay

肿瘤细胞自原发瘤体脱离后,降解基质、穿越基底膜并进入血管内是完成转移的关键步骤之一。肿瘤细胞的运动能力是能否完成该过程的重要因素,是肿瘤浸润周围组织、发生远处转移的基本调节。

越来越多的证据表明,肿瘤细胞与血管内皮层的粘附受到内皮层激活或内皮细胞的组织特异性的影响,同时与一些特殊细胞表面分子的表达相关。选择素E(E-Selectin)和内皮细胞粘附分子1(VCAM-1)在肿瘤细胞-内皮细胞之间的作用中扮演了重要的角色。

Cell Biolabs的CytoSelect™ Tumor Transendothelial Migration Assay肿瘤细胞跨内皮迁移分析试剂盒提供了一个自动化定量肿瘤细胞与内皮细胞互相作用的实验方案,该实验方案内包括了用于包埋内皮细胞的培养板,使用TNFa等激活内皮细胞后,加入用CytoTracker™荧光标记的肿瘤细胞孵育培养2-24小时,擦拭去上层未发生迁移的肿瘤细胞,对发生游出的肿瘤细胞进行荧光定量。该系统能方便快捷的对肿瘤细胞与内皮细胞之间的粘附及夸内皮迁移进行定量分析,发生游出的肿瘤细胞可以经荧光平板读取器上直接定量。

产品名称 货号 产品说明(点击查看说明书)
CytoSelect™ Tumor Transendothelial Migration Assay CBA-216 荧光法检测,一次96孔板分析

Cell BioLabs为您提供全套的细胞分析检测方案,针对于细胞迁移,除了肿瘤细胞跨内皮迁移分析方案外,还有针对白细胞的游出分析,以及细胞的趋化特征和趋触特性的分析。另外,Cell Biolabs还开发出其他多方位的基于细胞功能特征,特别是肿瘤细胞的特性的克隆形成、细胞粘附、细胞转移与浸润、细胞吞噬快速分析、细胞活力/死亡/毒性分析、细胞衰老及收缩检测,以及血管生成分析等多种分析试剂盒。如果您对上述细胞分析方案感兴趣,请致电021-50837765到上海金畔生物科技有限公司垂询细胞研究的相关实验解决方案,或索取最新的Cell BioLabs产品资料。

Angiotensin I 血管紧张素I 品牌:FUJIFILM Wako


Angiotensin I

血管紧张素I

品牌:FUJIFILM Wako
CAS No.:
储存条件:-20℃
纯度:97.0+% (HPLC)
产品编号

(生产商编号)

等级 规格 运输包装 零售价(RMB) 库存情况 参考值

012-18153

for Biochemistry 10 mg

Angiotensin I                                                      血管紧张素I            品牌:FUJIFILM Wako

替代品:014-28003


* 干冰运输、大包装及大批量的产品需酌情添加运输费用


* 零售价、促销产品折扣、运输费用、库存情况、产品及包装规格可能因各种原因有所变动,恕不另行通知,确切详情请联系上海金畔生物科技有限公司。